Ruta graveolens

Within the SIRIAM Platform, Ruta graveolens is incorporated as a botanical Release Core Component that contributes to the functional identity of the Release phase.

Unlike Structural & Dermal Support Core ingredients, Ruta graveolens is included because of its botanical pharmacological profile rather than its contribution to the physical architecture of the formulation. It is intended to function as one of several complementary botanical ingredients within the Release Core, where each ingredient contributes distinct mechanistic characteristics while remaining part of a unified pharmaceutical system.

Ruta graveolens is not considered a Regional Signature Component. Instead, it serves as a common botanical ingredient that may be incorporated into multiple SIRIAM formulations according to the architectural requirements of the platform.

Its inclusion reflects the SIRIAM philosophy of combining established pharmaceutical formulation principles with carefully selected botanical compounds possessing biologically plausible mechanisms.

Ruta graveolens (Common Rue) has been used in traditional European and Mediterranean herbal medicine for centuries. The aerial parts of the plant contain a complex mixture of biologically active compounds, including flavonoids (particularly rutin), furanocoumarins, alkaloids and volatile oils.

Experimental studies have demonstrated several biological activities, including modulation of inflammatory mediators, antioxidant activity, smooth muscle effects and vascular interactions. In vitro investigations have also reported effects on selected cytokine pathways and oxidative stress mechanisms.

Human clinical evidence, however, remains limited. Most available data originate from laboratory studies, animal models or traditional medicinal use rather than high-quality controlled clinical trials.

Topical research involving Ruta graveolens is particularly scarce. Existing publications focus mainly on experimental pharmacology or traditional applications rather than standardized pharmaceutical topical formulations.

Importantly, Ruta graveolens also contains naturally occurring furanocoumarins, compounds capable of inducing phototoxic reactions following ultraviolet (UV) exposure. This characteristic is well documented and represents an important pharmaceutical consideration when developing topical preparations.

Current scientific evidence therefore provides biological plausibility but limited direct clinical evidence for topical application.

No published studies currently evaluate Ruta graveolens within a region-specific neurodermal formulation system comparable to the SIRIAM Platform. Consequently, its incorporation reflects the platform's formulation philosophy and ongoing pharmaceutical development rather than established evidence for this specific application.

Within the SIRIAM Platform, Ruta graveolens functions as a botanical Release Core ingredient.

Its purpose is to contribute to the functional diversity of the Release architecture while remaining independent of regional anatomical differentiation.

Its precise concentration and botanical standardisation remain subject to ongoing pharmaceutical optimisation.